Objective To observe the clinical curative effect of Ⅲb~Ⅳstage non-small cell lung cancer treated by radiofrequency ablation combined with chemotherapy. Methods Forty-eight Ⅲb~Ⅳstage non-small cell lung cancer patients were divided into the study group (RFA + chemotherapy) and 74 were in control group (chemotherapy alone) by the method of non randomized controlled. Curative effect was evaluated every two cycles during the treatment. A 6 to 36 months follow-up was conducted after the treatment. Results The objective response rate of experiment group and control group was 58.3%and 41.9%respectively (P>0.05) with no significant difference and disease control rates of experiment group and control group were 91.7% and 75.7% respectively (P<0.05). MST were 14.4 months and 8.2 months respectively (P<0.01), with statistically significant differences in experiment group and control group and clinical benefit efficient were 87 . 5% and 66 . 2% respectively ( P < 0.05). Conclusion The treatment of radiofrequency ablation combined with chemotherapy for advanced non-small cell lung cancer can significantly improve the patient′s survival and the clinical curative effect.%目的：观察射频消融联合化疗治疗Ⅲb～Ⅳ期非小细胞肺癌的临床疗效。方法：从2011年1月至2013年12月，采用非随机对照的方法，将符合纳入标准的Ⅲb～Ⅳ期中晚期非小细胞肺癌患者按治疗意愿分为研究组（射频联合化疗）48例和对照组（单纯化疗）74例。对照组采用DP或GP方案，研究组采用上述化疗方案联合射频消融方法治疗。治疗期间每2个化疗周期进行一次疗效评估。治疗结束后开始对患者进行6～36个月的随访。结果：研究组和对照组的客观有效率分别为58．3％和41．9％（P ＞0．05）；疾病控制率分别为91．7％和75．7％（P ＜0．05）；临床受益有效率分别为87．5％和66．2％（P ＜0．05）； MST分别为14．4个月和8．2个月（P ＜0．O1）。结论：射频消融结合化疗治疗Ⅲb～Ⅳ期非小细胞肺癌可减轻患者症状，延长生存期，具有较好的应用前景。
展开▼
